RT Journal Article
SR Electronic
T1 Interplay of IL6 and CRIM1 on thiopurine-induced neutropenia in leukemic patients with wild-type NUDT15 and TPMT
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.21.20158931
DO 10.1101/2020.07.21.20158931
A1 Hyery Kim
A1 Seungwon You
A1 Yoomi Park
A1 Jung Yoon Choi
A1 Youngeun Ma
A1 Kyung Tak Hong
A1 Kyung-Nam Koh
A1 Sunmin Yun
A1 Kye Hwa Lee
A1 Hee Young Shin
A1 Suehyun Lee
A1 Keon Hee Yoo
A1 Ho Joon Im
A1 Hyoung Jin Kang
A1 Ju Han Kim
YR 2020
UL http://medrxiv.org/content/early/2020/07/25/2020.07.21.20158931.abstract
AB Background NUDT15 and TPMT variants are strong genetic determinants of thiopurine-induced hematological toxicity. Despite recent discovery of homozygous CRIM1 effect on thiopurine toxicity, many patients with wild-type NUDT15, TPMT, and CRIM1 still suffer from thiopurine toxicity, and therapeutic failure and relapse of acute lymphoblastic leukemia (ALL).Methods Novel PGx interactions associated with thiopurine toxicity in 320 pediatric ALL patients were investigated using whole-exome sequencing technology for the last-cycle 6-Mercaptopurine dose intensity percentage (DIP) tolerated by pediatric ALL patients.Results IL6 rs13306435 carriers (N=19) exhibited significantly lower DIP (48.0±27.3%) than non-carriers (N=209, 69.9±29.0%; p=0.0016 and 0.0028 by t-test and multiple linear regression, respectively). Of the 19 carriers, seven with both heterozygous IL6 rs13306435 and CRIM1 rs3821169 showed significantly decreased DIP (24.7±8.9%) than those with IL6 (N=12, 61.6±25.1%) or CRIM1 (N=94, 68.1±28.4%) variant only. Both IL6 and CRIM1 variants showed marked inter-ethnic variability. Significant interplay between IL6 and CRIM1 in thiopurine toxicity was suggested. GVB (Gene-wise Variant Burden)-based four-gene-interplay model showed the best odds ratio (8.06) and potential population impact (i.e., relative risk (5.73), population attributable fraction (58%), number needed to treat (3.67) and number needed to genotype (12.50)).Conclusions Interplay of IL6 rs13306435 and CRIM1 rs3821169 was suggested as independent and/or additive genetic determinant of thiopurine toxicity beyond NUDT15 and TPMT in pediatric ALL.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by a grant (16183MFDS541) from Ministry of Food and Drug Safety in 2019.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the AMC Review Boards, the SMC Review Boards, and the SNUH Review Boards.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author.